CCN3-EZH2-AR feedback loop: new targets for enzalutamide and castration resistant prostate cancer
Cameron M Armstrong1, Allen C Gao2
1Department of Urology, UC Davis Comprehensive Cancer Center, University of California Davis, Davis, CA, USA.
Abstract:
The development of castration resistant prostate cancer and anti-androgen resistance remains one of the largest hurdles in the successful treatment of prostate cancer. Therefore, the identification of dysregulated pathways contributing to this resistance and determining ways to target these mechanisms is of utmost importance. In the recent publication in Cancer Research, Fong et al. identify a novel role for cytoplasmic CCN3 in prostate cancer progression and enzalutamide resistance. The authors demonstrate that CCN3 expression inhibits androgen receptor signaling and thereby suppresses enzalutamide-resistant prostate cancer cell proliferation, colony formation, and xenograft tumor growth. The data from this manuscript highlight an intriguing potential therapeutic target for the treatment of CRPC and are a critical step forwards towards treating enzalutamide resistant prostate cancer.
Insights
Cytoplasmic CCN3 inhibits androgen receptor signaling, suppressing prostate cancer growth and enzalutamide resistance. This finding identifies CCN3 as a potential therapeutic target for castration-resistant prostate cancer (CRPC).
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Castration-resistant prostate cancer (CRPC) and anti-androgen resistance are significant challenges in treatment.
- Identifying dysregulated pathways driving resistance is crucial for therapeutic development.
Purpose of the Study:
- To investigate the role of cytoplasmic CCN3 in prostate cancer progression and enzalutamide resistance.
- To explore CCN3 as a potential therapeutic target for advanced prostate cancer.
Main Methods:
- Analysis of CCN3 expression in prostate cancer models.
- Assessment of CCN3's impact on androgen receptor signaling pathways.
- Evaluation of CCN3's effects on cell proliferation, colony formation, and xenograft tumor growth in enzalutamide-resistant models.
Main Results:
- CCN3 expression was found to inhibit androgen receptor signaling.
- Increased CCN3 suppressed enzalutamide-resistant prostate cancer cell proliferation and colony formation.
- CCN3 inhibited xenograft tumor growth in models of enzalutamide-resistant prostate cancer.
Conclusions:
- Cytoplasmic CCN3 plays a novel role in suppressing prostate cancer progression and enzalutamide resistance.
- CCN3 represents a promising therapeutic target for treating castration-resistant prostate cancer.
- This research advances strategies for overcoming anti-androgen resistance in prostate cancer treatment.
